Molecular Immunology

Molecular Immunology is published by Elsevier Ltd and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Monoclonal and Polyclonal Antibodies Research, T-cell and B-cell Immunology and Complement system in diseases, together about 35.4% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)

Molecular Immunology publishes original articles, reviews and commentaries on all areas of immunology, with a particular focus on description of cellular, biochemical or genetic mechanisms underlying immunological phenomena. Studies on all model organisms, from invertebrates to humans, are suitable. Examples include, but are not restricted to:Infection, autoimmunity, transplantation, immunodeficiencies, inflammation and tumor immunologyMechanisms of induction, regulation and termination of innate and adaptive immunityIntercellular communication, cooperation and regulationIntracellular mechanisms of immunity (endocytosis, protein trafficking, pathogen recognition, antigen presentation, etc)Mechanisms of action of the cells and molecules of the immune systemStructural analysisDevelopment of the immune systemComparative immunology and evolution of the immune system"Omics" studies and bioinformaticsVaccines, biotechnology and therapeutic manipulation of the immune system (therapeutic antibodies, cytokines, cellular therapies, etc)Technical developmentsArticles based primarily on studies in silico must adhere to the following principles; (i) The article must report novel analytical tools, approaches and/or databases rather than using publicly available ones; or (ii) The article must include substantial experimental validation of the conclusions obtained in silico.Manuscripts related to regulatory RNA (e.g. microRNAs, lncRNAs or circRNAs) are welcome but please note: (i) they must show clear physiological relevance supported by in vivo results or clinical observations; (ii) Correlations between regulatory RNA expression with human diseases should be experimentally validated; (iii) Functions associated with the regulatory RNAs must within the scope of the journal i.e. inflammation and/or immune responses.To be acceptable for publication, studies that describe correlations between disease and genetic polymorphisms would normally be required to include novel mechanistic findings underlying the associations.Clinical studies correlating disease and measurements of a molecule or cell type would likewise not be suitable for publication without novel mechanistic insights.Studies describing pharmacological agents are welcome if they provide significant novelty on the mechanisms of action.

From the journal's Aims & Scope

Research area (LetPub): Immunology

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

3.65LetPub · 2026-09-13

Impact factor (publisher)

3.7Publisher website · 2026-09-29

CiteScore 2026-06

6.1LetPub · 2026-09-13

CiteScore (publisher)

6.1Publisher website · 2026-09-29

SJR 2026-06

0.97LetPub · 2026-09-13

SNIP 2026-06

0.77LetPub · 2026-09-13

h-index

113LetPub · 2026-09-13

h-index

182OpenAlex · 2026-10-01

i10-index

6,772OpenAlex · 2026-10-01

2-year mean citedness

3.12OpenAlex · 2026-10-01

Self-citation rate

2.7%LetPub · 2026-09-13

Share of gold OA articles

25.61%LetPub · 2026-09-13

Volume

Articles per year

198LetPub · 2026-09-13

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

about 2 monthsLetPub · 2026-09-13

Average acceptance (community reports)

62.5%LetPub · 2026-09-13

Submission to first decision

2 daysPublisher website · 2026-09-29

First decision after review

41 daysPublisher website · 2026-09-29

Submission to acceptance

96 daysPublisher website · 2026-09-29

Acceptance to publication

8 daysPublisher website · 2026-09-29

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Elsevier Ltd

Country or region

ENGLAND

Language

Multi-Language

Frequency

Semimonthly

Founded

1979

ISSN

0161-5890

Electronic ISSN

1872-9142

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗Publisher website
• Special issues ↗Publisher website